Nephros (NEPH) Competitors $3.57 +0.13 (+3.78%) Closing price 07/25/2025 03:59 PM EasternExtended Trading$3.60 +0.03 (+0.84%) As of 07/25/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NEPH vs. LNSR, ELMD, PDEX, PTHL, RCEL, LAKE, LUNG, BSGM, LUCD, and OBIOShould you be buying Nephros stock or one of its competitors? The main competitors of Nephros include LENSAR (LNSR), Electromed (ELMD), Pro-Dex (PDEX), Pheton (PTHL), Avita Medical (RCEL), Lakeland Industries (LAKE), Pulmonx (LUNG), Biosig Technologies (BSGM), Lucid Diagnostics (LUCD), and Orchestra BioMed (OBIO). These companies are all part of the "medical equipment" industry. Nephros vs. Its Competitors LENSAR Electromed Pro-Dex Pheton Avita Medical Lakeland Industries Pulmonx Biosig Technologies Lucid Diagnostics Orchestra BioMed Nephros (NASDAQ:NEPH) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation. Do insiders and institutionals believe in NEPH or LNSR? 41.1% of Nephros shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 6.7% of Nephros shares are held by insiders. Comparatively, 38.5% of LENSAR shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor NEPH or LNSR? In the previous week, LENSAR had 1 more articles in the media than Nephros. MarketBeat recorded 2 mentions for LENSAR and 1 mentions for Nephros. Nephros' average media sentiment score of 1.89 beat LENSAR's score of 1.87 indicating that Nephros is being referred to more favorably in the media. Company Overall Sentiment Nephros Very Positive LENSAR Very Positive Which has preferable valuation and earnings, NEPH or LNSR? Nephros has higher earnings, but lower revenue than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNephros$14.16M2.67$70K$0.0751.00LENSAR$53.49M2.88-$31.40M-$4.85-2.69 Do analysts rate NEPH or LNSR? Nephros presently has a consensus price target of $5.00, indicating a potential upside of 40.06%. LENSAR has a consensus price target of $15.00, indicating a potential upside of 14.94%. Given Nephros' stronger consensus rating and higher possible upside, equities analysts clearly believe Nephros is more favorable than LENSAR.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00LENSAR 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, NEPH or LNSR? Nephros has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Is NEPH or LNSR more profitable? Nephros has a net margin of 5.16% compared to LENSAR's net margin of -99.17%. Nephros' return on equity of 9.43% beat LENSAR's return on equity.Company Net Margins Return on Equity Return on Assets Nephros5.16% 9.43% 7.20% LENSAR -99.17%-737.30%-81.69% SummaryNephros beats LENSAR on 12 of the 16 factors compared between the two stocks. Get Nephros News Delivered to You Automatically Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEPH vs. The Competition Export to ExcelMetricNephrosMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.47M$10.55B$5.70B$9.50BDividend YieldN/A2.00%4.69%4.01%P/E Ratio51.0117.0728.1020.06Price / Sales2.6729.18428.7189.10Price / Cash171.9123.0336.2258.56Price / Book4.413.698.665.87Net Income$70K$234.77M$3.25B$258.55M7 Day Performance-1.92%6.32%4.22%3.73%1 Month Performance-15.80%7.94%10.51%11.75%1 Year Performance60.45%-13.57%34.40%18.02% Nephros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEPHNephros3.2201 of 5 stars$3.57+3.8%$5.00+40.1%+61.5%$36.47M$14.16M51.0130LNSRLENSAR1.2718 of 5 stars$13.32+1.7%$15.00+12.6%+143.0%$154.48M$53.49M-2.75110Positive NewsELMDElectromed1.2781 of 5 stars$18.13-0.5%$38.00+109.6%+26.9%$152.04M$61.44M24.17160News CoverageAnalyst ForecastAnalyst RevisionPDEXPro-Dex2.4778 of 5 stars$46.66+1.0%$56.00+20.0%+159.1%$150.63M$64.12M16.66140PTHLPhetonN/A$22.61+1.8%N/AN/A$146.25M$450K0.0011Positive NewsGap UpHigh Trading VolumeRCELAvita Medical1.341 of 5 stars$5.21+0.8%$16.50+216.7%-43.4%$136.67M$64.25M-2.38130Positive NewsLAKELakeland Industries4.7544 of 5 stars$14.14+0.7%$26.00+83.9%-37.0%$133.59M$167.21M0.002,100News CoverageLUNGPulmonx3.5908 of 5 stars$3.18+1.0%$11.53+262.4%-57.4%$126.81M$83.79M-2.21250News CoverageUpcoming EarningsBSGMBiosig Technologies1.9472 of 5 stars$5.76+24.4%$10.00+73.6%+964.4%$126.37M$40K0.0050Gap UpHigh Trading VolumeLUCDLucid Diagnostics2.7064 of 5 stars$1.11-0.9%$3.55+219.8%+30.6%$121.17M$4.35M-0.8370OBIOOrchestra BioMed3.0897 of 5 stars$3.16+2.3%$14.20+349.4%-59.2%$118.39M$2.64M-1.784News CoveragePositive News Related Companies and Tools Related Companies LENSAR Competitors Electromed Competitors Pro-Dex Competitors Pheton Competitors Avita Medical Competitors Lakeland Industries Competitors Pulmonx Competitors Biosig Technologies Competitors Lucid Diagnostics Competitors Orchestra BioMed Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEPH) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredThe AI Chip Trade is OUT. This is in…Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredElon Musk: “This will transform civilization as we know it.”Robots are no longer science fiction — they’re the next trillion-dollar megatrend. According to Forbes, by ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.